BORTEZOMIB 3.5 mg/1 (Bortezomib INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 3.5 mg/1

Bortezomib 3.5 mg/1 is a lyophilized powder for solution, used for intravenous or subcutaneous administration. This medication is commonly associated with certain cancer treatments. Learn more about its uses and effects.

Strength

3.5 mg/1

Pack Size

1 VIAL in 1 CARTON (25021-262-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL

Manufacturer / TM Owner

Sagent Pharmaceuticals

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bortezomib 3.5 mg/1 is primarily used in the management of specific types of cancer. It works by interfering with the growth of cancer cells. Patients often wonder, 'What is Bortezomib used for?' This medication is typically prescribed for conditions where targeted therapy is required.

Side Effects

Common effects of Bortezomib 3.5 mg/1 may include fatigue, nausea, and peripheral neuropathy. Some individuals may experience gastrointestinal discomfort. These effects can vary widely among users, and it's important to consult a healthcare provider for personalized information.

Precautions & Warnings

Bortezomib 3.5 mg/1 should be handled with care, as it is a potent medication. It is essential to follow the prescribed dosage and administration guidelines. Patients with certain medical conditions or allergies should inform their healthcare provider before use.

Avoid Interactions

Bortezomib 3.5 mg/1 may interact with other medications, including those that affect the liver or immune system. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol consumption should also be considered, as it may exacerbate certain side effects.

Frequently Asked Questions

Bortezomib is commonly used in the treatment of certain types of cancer, particularly multiple myeloma and mantle cell lymphoma.

Bortezomib is available as a lyophilized powder for solution, which can be administered either intravenously or subcutaneously.

Common side effects may include fatigue, nausea, peripheral neuropathy, and gastrointestinal discomfort.

Bortezomib may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Patients should follow the prescribed dosage and administration guidelines, and inform their healthcare provider of any medical conditions or allergies.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.